Medical

Respira Therapeutics has announced that the results of Phase 1 and Phase 2a clinical studies of RT234-PAH dry powder vardenafil "support its further development as an as-needed (PRN) treatment that will allow patient-controlled dosing to acutely improve episodic symptoms and exercise capacity in pulmonary arterial hypertension (PAH) patients." The company is … [Read more...] about Positive Phase 1 and Phase 2a results for clinical trials of Respira’s vardenafil DPI

Avalyn Pharma said that idiopathic pulmonary fibrosis (IPF) patients who received the higher dose tested in a Phase 1/2 study of the company's AP01 pirfenidone inhalation solution "had a trend toward stabilization of lung function," while those on the lower dose continued a decline in lung function over 24 weeks. As a result, all of the patients who are continuing in … [Read more...] about Avalyn announces results of Phase 1/2 study of inhaled pirfenidone in IPF patients

Armata Pharmaceuticals announced that it plans to initiate clinical development of inhaled AP-PA02, a phage cocktail the company is developing for the treatment of P. aeruginosa infections in cystic fibrosis patients.  The SAD portion of the Phase 1b/2a SWARM-P.a. study is expected to begin by the end of 2020. Armata Pharmaceuticals CEO Todd R. … [Read more...] about Armata Pharmaceuticals announces plans for Phase 1b/2a trial of inhaled phage in CF patients

Ionis Pharmaceuticals has announced data from a Phase 1 SAD/MAD study of its IONIS-ENAC-2.5Rx nebulized antisense therapy in cystic fibrosis patients demonstrating a mean 55.6% reduction of epithelial sodium channel (ENaC) messenger RNA in cystic fibrosis patients who received a 75 mg dose in the MAD portion of the study. According to the company, preclinical studies … [Read more...] about Phase 1 study of Ionis inhaled antisense therapy in CF patients demonstrates significant reduction in ENaC messenger RNA

Israeli biopharma company Nasus Pharma says that it provided its Taffix intranasal hydroxypropyl methylcellulose (HPMC) powder to members of a synagogue for use during Rosh Hashana celebrations, and worshippers who used Taffix were infected with SARS-CoV-2 at one quarter the rate of those who did not use the nasal powder. The members of the synagogue were in close … [Read more...] about Nasus Pharma says its Taffix intranasal HPMC significantly reduced SARS-CoV-2 infection in real world superspreader event

Revelation Biosciences announced that the Australian Therapeutic Goods Administration has okayed a Phase 1 clinical study of the company's REVTx‑99 intranasal phosphorylated hexaacylated disaccharide (PHAD), which Revelation is developing for the treatment of COVID‑19. According to the company's web site, "REVTx-99 acts by stimulating the innate immune response via … [Read more...] about Revelation Biosciences announces Phase 1 trial of its intranasal PHAD

Researchers from the University of Texas at Austin and Chungnam National University have published in vitro and in vivo data demonstrating that a dry powder formulation of niclosamide that includes human lysozyme (hLYS) as a carrier exhibits potent activity against both the MERS-CoV and SARS-CoV-2 viruses. The article is available as a preprint on BioRxiv and is … [Read more...] about Studies show spray dried niclosamide/hLYS formulation has strong activity against SARS-CoV-2

Ena Respiratory (formerly Innavac) said that its INNA-051 pegylated TLR2/6 agonist nasal spray reduced replication of the SARS-CoV-2 virus in a ferret model by up to 96% in a study conducted by researchers at Public Health England. The company also announced that it has raised AU$11.7 million in Series A financing for a clinical trial that could begin by early 2021 … [Read more...] about Preclinical testing demonstrates that Ena Respiratory’s intranasal antiviral reduces replication of SARS-CoV-2

TFF Pharmaceuticals is drawing attention to in vitro data published by researchers at the University of Texas Austin which found that thin film freezing "produces high potency remdesivir dry powder formulations for inhalation suitable to treat patients with COVID-19 on an outpatient basis and earlier in the disease course where effective antiviral therapy can reduce … [Read more...] about UT Austin study concludes that TFF dry powder remdesivir is suitable as an inhaled therapy for COVID-19